ClinicalTrials.Veeva

Menu

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer

B

Bagcilar Training and Research Hospital

Status

Completed

Conditions

Breast Neoplasms

Study type

Observational

Funder types

Other

Identifiers

NCT01942759
BC-PET-MR-01

Details and patient eligibility

About

The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.

Full description

We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic value of these indexes in breast cancer in this study. The evaluated and compared parameters are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status, histologic grade, modified Nottingham prognostic index.

Enrollment

43 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Newly diagnosis of breast cancer for which surgical intervention is planned

Exclusion criteria

  • patients received neoadjuvant chemotherapy
  • before breast surgery

Trial design

43 participants in 6 patient groups

Histologic grade
Description:
According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
Axillary metastasis
Description:
Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
Modified Nottingham prognostic index
Description:
NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3) The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (\>5.4) prognostic groups
Oestrogen receptor status
Description:
Negative Positive
Progesterone receptor status
Description:
Negative Positive
HER-2 neu status
Description:
Negative Positive

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems